SG11201609722UA - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SG11201609722UA SG11201609722UA SG11201609722UA SG11201609722UA SG11201609722UA SG 11201609722U A SG11201609722U A SG 11201609722UA SG 11201609722U A SG11201609722U A SG 11201609722UA SG 11201609722U A SG11201609722U A SG 11201609722UA SG 11201609722U A SG11201609722U A SG 11201609722UA
- Authority
- SG
- Singapore
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014078701 | 2014-05-28 | ||
| PCT/CN2015/079755 WO2015180614A1 (en) | 2014-05-28 | 2015-05-26 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201609722UA true SG11201609722UA (en) | 2016-12-29 |
Family
ID=54698095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609722UA SG11201609722UA (en) | 2014-05-28 | 2015-05-26 | Novel compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9868724B2 (en) |
| EP (1) | EP3148987B1 (en) |
| JP (1) | JP6522665B2 (en) |
| KR (1) | KR20170008852A (en) |
| CN (1) | CN107001342B (en) |
| AU (1) | AU2015267911B2 (en) |
| CA (1) | CA2953637C (en) |
| CL (1) | CL2016003023A1 (en) |
| CR (1) | CR20160549A (en) |
| DO (1) | DOP2016000311A (en) |
| EA (1) | EA032272B1 (en) |
| ES (1) | ES2716966T3 (en) |
| IL (1) | IL248983A0 (en) |
| MX (1) | MX2016015631A (en) |
| PE (1) | PE20170137A1 (en) |
| PH (1) | PH12016502331A1 (en) |
| SG (1) | SG11201609722UA (en) |
| WO (1) | WO2015180614A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6279605B2 (en) | 2012-12-06 | 2018-02-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Modulators of retinoid-related orphan receptor gamma (RORγ) for use in the treatment of autoimmune and inflammatory diseases |
| KR20170012388A (en) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Novel compounds |
| AU2015267909B2 (en) | 2014-05-28 | 2018-03-22 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| SG11201609722UA (en) | 2014-05-28 | 2016-12-29 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10662181B2 (en) * | 2016-07-13 | 2020-05-26 | Leo Pharma A/S | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| CN109134476B (en) * | 2017-06-15 | 2021-03-19 | 复旦大学 | Bridged ring piperazine derivative or salt thereof, and preparation method and application thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| EP2511263A1 (en) | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| US8604069B2 (en) | 2011-04-28 | 2013-12-10 | Japan Tobacco Inc. | Amide compound and medicinal use thereof |
| WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| CA2847563A1 (en) * | 2011-09-09 | 2013-03-14 | New York University | Amido compounds as ror.gamma.t modulators and uses thereof |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| WO2013100027A1 (en) * | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | Heterocyclic compound |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| JP6182594B2 (en) | 2012-04-27 | 2017-08-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | New compounds |
| JO3215B1 (en) * | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy |
| NZ706775A (en) * | 2012-10-16 | 2018-10-26 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
| JP6279605B2 (en) * | 2012-12-06 | 2018-02-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Modulators of retinoid-related orphan receptor gamma (RORγ) for use in the treatment of autoimmune and inflammatory diseases |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| US20160257664A1 (en) | 2013-10-25 | 2016-09-08 | Glaxosmithkline Llc | Novel compounds |
| US10286000B2 (en) | 2013-10-25 | 2019-05-14 | St. Jude Children's Research Hospital, Inc. | Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer |
| AU2015267909B2 (en) | 2014-05-28 | 2018-03-22 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| SG11201609722UA (en) | 2014-05-28 | 2016-12-29 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20170012388A (en) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Novel compounds |
-
2015
- 2015-05-26 SG SG11201609722UA patent/SG11201609722UA/en unknown
- 2015-05-26 CA CA2953637A patent/CA2953637C/en active Active
- 2015-05-26 ES ES15800053T patent/ES2716966T3/en active Active
- 2015-05-26 US US15/314,107 patent/US9868724B2/en active Active
- 2015-05-26 EP EP15800053.9A patent/EP3148987B1/en active Active
- 2015-05-26 KR KR1020167036018A patent/KR20170008852A/en unknown
- 2015-05-26 CR CR20160549A patent/CR20160549A/en unknown
- 2015-05-26 CN CN201580039289.0A patent/CN107001342B/en active Active
- 2015-05-26 JP JP2016569773A patent/JP6522665B2/en active Active
- 2015-05-26 WO PCT/CN2015/079755 patent/WO2015180614A1/en active Application Filing
- 2015-05-26 MX MX2016015631A patent/MX2016015631A/en unknown
- 2015-05-26 PE PE2016002268A patent/PE20170137A1/en not_active Application Discontinuation
- 2015-05-26 AU AU2015267911A patent/AU2015267911B2/en not_active Ceased
- 2015-05-26 EA EA201692395A patent/EA032272B1/en not_active IP Right Cessation
-
2016
- 2016-11-15 IL IL248983A patent/IL248983A0/en unknown
- 2016-11-23 PH PH12016502331A patent/PH12016502331A1/en unknown
- 2016-11-24 CL CL2016003023A patent/CL2016003023A1/en unknown
- 2016-11-28 DO DO2016000311A patent/DOP2016000311A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015267911B2 (en) | 2017-10-26 |
| US20170101399A1 (en) | 2017-04-13 |
| EA201692395A1 (en) | 2017-03-31 |
| ES2716966T3 (en) | 2019-06-18 |
| IL248983A0 (en) | 2017-01-31 |
| KR20170008852A (en) | 2017-01-24 |
| CA2953637C (en) | 2022-11-29 |
| CR20160549A (en) | 2017-04-28 |
| CL2016003023A1 (en) | 2017-04-21 |
| EP3148987B1 (en) | 2019-01-02 |
| AU2015267911A1 (en) | 2016-12-01 |
| WO2015180614A1 (en) | 2015-12-03 |
| PE20170137A1 (en) | 2017-03-05 |
| CN107001342A (en) | 2017-08-01 |
| DOP2016000311A (en) | 2017-02-28 |
| US9868724B2 (en) | 2018-01-16 |
| PH12016502331A1 (en) | 2017-02-06 |
| JP2017519738A (en) | 2017-07-20 |
| CA2953637A1 (en) | 2015-12-03 |
| JP6522665B2 (en) | 2019-05-29 |
| CN107001342B (en) | 2020-02-07 |
| MX2016015631A (en) | 2017-04-25 |
| EP3148987A4 (en) | 2017-11-15 |
| EA032272B1 (en) | 2019-05-31 |
| EP3148987A1 (en) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250345A0 (en) | Novel compounds | |
| IL250592A0 (en) | Novel compounds | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| GB201417011D0 (en) | Novel compounds | |
| GB201417094D0 (en) | Novel compounds | |
| GB201417018D0 (en) | Novel compounds | |
| GB201402431D0 (en) | Compounds | |
| SG11201606693SA (en) | Novel compounds | |
| GB201405991D0 (en) | Novel compounds | |
| GB201411239D0 (en) | Novel compounds | |
| GB201411236D0 (en) | Novel compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201404002D0 (en) | Novel compounds | |
| GB201406591D0 (en) | Compounds | |
| GB201406956D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| IL248983A0 (en) | Novel compounds | |
| GB201419102D0 (en) | Novel compounds | |
| GB201405361D0 (en) | Compounds | |
| ZA201605726B (en) | Novel compounds | |
| GB201421834D0 (en) | Novel compounds | |
| GB201421784D0 (en) | Novel compounds | |
| GB201417043D0 (en) | Novel compounds | |
| GB201417041D0 (en) | Novel compounds | |
| GB201417021D0 (en) | Novel compounds |